Johannes Ammann

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

Kristina Schwamborn, Johannes Ammann, Ruth Knüchel et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2019 · 58 citations · Full text

Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients

Oliver Schmalz, Christine Jacob, Johannes Ammann et al. · Journal of Medical Internet Research · 2020 · 51 citations · Full text

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany

Josef Rüschoff, Annette Lebeau, Hans Kreipe et al. · Modern Pathology · 2016 · 41 citations · Full text

Breast Oncology, Medicine, Epidemiology Of Cancer +6

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 immunohistochemistry assays for scoring in triple‐negative breast cancer

Aurelia Noske, Johannes Ammann, Daniel‐Christoph Wagner et al. · Histopathology · 2020 · 27 citations · Full text

Swiss adjuvant trial (OSAKO 06/74) with chlorambucil, methotrexate, and 5-fluorouracil plus BCG in node-negative breast cancer patients: nine-year results.

Senn Hj, Jungi Wf, R Amgwerd et al. · PubMed · 1986 · 15 citations

Between 1974, Surgical Oncology, Breast Oncology +16